Brisbane's Princess Alexandra Hospital haematology department manages myeloma and lymphoma patients from across Queensland requiring Bortezomib-based combination regimens. Bortenat 3.5mg injection vials provide Brisbane's oncology pharmacies with reliable, WHO-GMP certified Bortezomib at significantly reduced institutional cost compared to brand Velcade for Queensland Health procurement teams.
Queensland's significant Pacific Islander and Southeast Asian communities — among whom multiple myeloma carries specific incidence patterns — access haematological cancer care through Brisbane's leading hospitals. Generic Bortenat's full TGA-compatible documentation package supports Queensland institutional pharmacy formulary approval processes.
Visit medshopy.com or WhatsApp +91 82650 41513 for Brisbane and Queensland supply.
Queensland's significant Pacific Islander and Southeast Asian communities — among whom multiple myeloma carries specific incidence patterns — access haematological cancer care through Brisbane's leading hospitals. Generic Bortenat's full TGA-compatible documentation package supports Queensland institutional pharmacy formulary approval processes.
Visit medshopy.com or WhatsApp +91 82650 41513 for Brisbane and Queensland supply.
What is the Dara-VRd regimen and is it replacing standard VRd for myeloma in Australia?Dara-VRd (Daratumumab + Bortezomib + Lenalidomide + dexamethasone) is an enhanced four-drug induction regimen that adds Daratumumab — an anti-CD38 monoclonal antibody — to the established VRd triple combination. The GRIFFIN and PERSEUS trials demonstrated that Dara-VRd produces significantly deeper responses including higher MRD negativity rates compared to standard VRd, translating into improved progression-free survival in transplant-eligible newly diagnosed myeloma. In Australia, PBS listing of Daratumumab for front-line myeloma has been progressively expanding, and Brisbane's Princess Alexandra haematology team evaluates each newly diagnosed transplant-eligible patient for Dara-VRd versus VRd based on PBS eligibility, individual risk profile, and patient preference. Bortenat (generic Bortezomib) remains the essential proteasome inhibitor component in both regimens.
